Medical Device | December 08, 2021
Venair showcases its Vena Flexip and Flexpure
The company plans to expand their capacity to meet the needs of pharma and biotech industries
The company plans to expand their capacity to meet the needs of pharma and biotech industries
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech
The hospital successfully treats two complex high-risk cardiac patients using advanced minimally invasive heart surgeries
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
Real-time remote collaboration during robotic-assisted cholecystectomy showcases new possibilities for surgical mentoring, education, and knowledge sharing across institutions
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand
Subscribe To Our Newsletter & Stay Updated
